New hope for head and neck cancer patients who failed standard treatment
Disease control
Ongoing
This study tests a new combination of drugs (LVGN6051, toripalimab, and paclitaxel) in 64 adults with advanced head and neck cancer that came back or spread after platinum-based treatment. The goal is to see if the combination is safe and shrinks tumors. Participants must be 18 o…
Phase: PHASE2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated May 26, 2026 07:25 UTC